CTLA4 and melanoma: We therefore propose that COX-2 levels and COX-dependent inflammatory mediators in human melanoma and other cancers might constitute useful biomarkers predictive of prognosis and treatment outcome, including in response to checkpoint blockade inhibitors, such as anti-CTLA4 and anti-PD-1/PD-L1.